Proactive Investors - Run By Investors For Investors

BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

BrainStorm Cell Therapeutics (NASDAQ:BCLI) CMO Dr. Ralph Kern sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The biotechnology company is developing a patient's own stem cell therapies for highly debilitating neurodegenerative disease. Its platform technology, NurOwn, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons.

View full BCLI profile View Profile

BrainStorm Cell Therapeutics Inc. Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use